The effect of low dose human chorionic gonadotropin on follicular response and oocyte maturation in PCOS patients undergoing IVF cycles: a randomized clinical trial of efficacy and safety

What Was Tested

The paper reports a study of hCG (human chorionic gonadotropin) in the context of pcos, published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are adults, women only.

Ninety women with PCOS who underwent assisted reproduction were eligible for this controlled, prospective, randomized study.

Patients were randomized using a block randomization technique which assigned them to three groups: group A (control group) continued r-FSH until oocyte retrieval.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the hCG (human chorionic gonadotropin) group and the comparison group should start out alike.

The methods mention a period of 24 months.

Their trial was performed at Royan Institute Reproductive Research Center over a 24-month period.

The main outcome measure was follicular response and oocyte maturation.

What Was Measured

PubMed files the paper under topics including Chorionic Gonadotropin, Fertilization in Vitro, Follicle Stimulating Hormone, Oogenesis, Ovarian Follicle, Ovulation Induction and Polycystic Ovary Syndrome.

What This Means in Plain Language

The paper is a randomized study of hCG (human chorionic gonadotropin) in people with pcos over 24 months.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (Archives of gynecology and obstetrics), a journal based in Germany.

More context: the hCG (human chorionic gonadotropin) compound page, PCOS research.